journal
Journals American Journal of Clinical D...

American Journal of Clinical Dermatology

https://read.qxmd.com/read/39369127/the-potential-role-of-cannabidiol-in-cosmetic-dermatology-a-literature-review
#1
REVIEW
Ai Kuzumi, Asako Yoshizaki-Ogawa, Takemichi Fukasawa, Shinichi Sato, Ayumi Yoshizaki
Cannabidiol (CBD) is a non-psychotropic cannabinoid with multiple pharmacological properties. Cannabidiol has attracted growing attention in the cosmetic industry, with an increasing number of CBD-containing skincare products on the market in recent years. The aim of this review is to evaluate the current evidence on the use of CBD for cosmetic purposes. Following an overview of CBD and the endocannabinoid system in the skin, we summarize pre-clinical and clinical studies that address the potential of CBD in cosmetic dermatology...
October 5, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/39348008/deciphering-the-etiologies-of-adult-erythroderma-an-updated-guide-to-presentations-diagnostic-tools-pathophysiologies-and-treatments
#2
REVIEW
Yanzhen Pang, William Q Nguyen, Liliana I Guerrero, Lauren P Chrisman, Madeline J Hooper, Morgan C McCarthy, Molly K Hales, Rachel E Lipman, Amy S Paller, Joan Guitart, Xiaolong A Zhou
Erythroderma, an inflammatory skin condition characterized by widespread erythema with variable degrees of exfoliation, pustulation, or vesiculobullous formation, is associated with high morbidity and mortality. Determining the underlying cause of erythroderma frequently presents a diagnostic challenge, which may contribute to the condition's relatively poor prognosis. This review covers the clinical presentation, pathophysiology, diagnosis, and treatment of erythroderma. It discusses similarities and differences among the many underlying etiologies of the condition and differences between erythrodermic and non-erythrodermic presentations of the same dermatosis...
September 30, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/39348007/comparing-tretinoin-to-other-topical-therapies-in-the-treatment-of-skin-photoaging-a-systematic-review
#3
JOURNAL ARTICLE
Zoya Siddiqui, Alina Zufall, Marissa Nash, Divya Rao, Rahim Hirani, Marian Russo
BACKGROUND: Many morphological and histological changes take place in aging skin. Topical tretinoin is the gold standard anti-aging agent used to reduce signs of aging through stimulation of epidermal growth and differentiation and inhibition of collagenase. OBJECTIVE: The aim of this systematic review is to summarize studies evaluating the efficacy of tretinoin compared with other topical medications and cosmeceuticals in reducing the appearance of skin aging. METHODS: A systematic review was conducted following the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines...
September 30, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/39327404/real-world-evidence-on-dose-spacing-of-il-23-inhibitors-in-the-treatment-of-psoriasis
#4
LETTER
Martim Luz, Tiago Torres
No abstract text is available yet for this article.
September 27, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/39300011/chronic-hand-eczema
#5
REVIEW
Elke Weisshaar
Chronic hand eczema (CHE) is a complex, challenging, and frequently multifactorial skin disease of the hands. It is very common in the general population, especially in certain professions. When hand eczema (HE) persists for longer than 3 months or has a minimum of two relapses per year after initial manifestation with complete clearance, it is considered chronic. In this case, health-related quality of life and the patient's working life are often impaired. CHE can be considered as an umbrella term because it covers different clinical pictures and etiologies...
September 19, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/39298112/kecort-study-an-international-e-delphi-study-on-the-treatment-of-keloids-using-intralesional-corticosteroids-in-clinical-practice
#6
JOURNAL ARTICLE
Qi Yin, Albert Wolkerstorfer, Oren Lapid, Khatera Qayumi, Murad Alam, Firas Al-Niaimi, Ofir Artzi, Martijn B A van Doorn, Ioannis Goutos, Merete Haedersdal, Chao-Kai Hsu, Woraphong Manuskiatti, Stan Monstrey, Thomas A Mustoe, Rei Ogawa, David Ozog, Tae Hwan Park, Julian Pötschke, Anthony Rossi, Swee T Tan, Luc Téot, Fiona M Wood, Nanze Yu, Susan Gibbs, Frank B Niessen, Paul P M van Zuijlen
BACKGROUND: Intralesional corticosteroid administration (ICA) is a first-line keloid treatment. However, it faces significant variability in current clinical and scientific practice, which hinders comparability of treatment results. OBJECTIVES: The aim of the study was to reach consensus on different aspects of ICA using hypodermic needles in keloids among an international group of dermatologists and plastic surgeons specialized in keloid treatment to provide consensus-based clinical treatment recommendations for all physicians treating keloids...
September 19, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/39283586/predicting-the-time-to-relapse-following-withdrawal-from-different-biologics-in-patients-with-psoriasis-who-responded-to-therapy-a-12-year-multicenter-cohort-study
#7
JOURNAL ARTICLE
Yu-Huei Huang, Sung Jen Hung, Chaw-Ning Lee, Nan-Lin Wu, Rosaline Chung-Yee Hui, Tsen-Fang Tsai, Chang-Ming Huang, Hsien-Yi Chiu
BACKGROUND: For patients with psoriasis, discontinuation of biologics following remission has become more common in daily practice. OBJECTIVE: We aimed to identify predictors and construct a predictive model for time to relapse following withdrawal from biologics. METHODS: This 12-year, multicenter, observational cohort study was performed in six dermatology centers between February 2011 and February 2024. We identified biological treatment episodes in patients with moderate-to-severe psoriasis and included only treatment episodes in which a clinical response (≥ 50% reduction in Psoriasis Area and Severity Index score [PASI 50] from baseline) was achieved and the patient withdrew from biological therapy with a well-controlled status (PASI < 10 and ≥ 50% improvement in PASI from baseline)...
September 16, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/39278968/update-on-stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-diagnosis-and-management
#8
REVIEW
Hemali Shah, Rose Parisi, Eric Mukherjee, Elizabeth J Phillips, Roni P Dodiuk-Gad
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are the most severe cutaneous adverse reactions that are typically drug-induced in adults. Both SJS and TEN have high morbidity and mortality rates. SJS/TEN imposes clinical challenges for physicians managing patients suffering from this condition, both because it is rare and because it is a rapidly progressing systemic disease with severe cutaneous, mucosal, and systemic manifestations. Although many cases of SJS/TEN have been reported in the literature, there is no consensus regarding diagnostic criteria or treatment...
September 15, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/39271603/a-practice-approach-to-acne-fulminans-in-adolescents
#9
JOURNAL ARTICLE
Nicolas G Quan, Remie Chrabieh, Mona Sadeghpour, Lucinda L Kohn
Acne fulminans (AF) is a severe form of inflammatory acne commonly associated with adolescents. It is characterized by an abrupt onset of painful nodules and plaques and can progress to suppurative, ulcerative, and hemorrhagic lesions. AF can be associated with systemic symptoms such as fever, arthralgia, and bone pain. The etiology of AF is unknown but it has been linked to the use of certain medications and has been rarely found in autoinflammatory syndromes. In previous years, there have been reports of <200 cases in the literature; however, AF may be more common in clinical practice than reported...
September 13, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/39259262/image-based-artificial-intelligence-in-psoriasis-assessment-the-beginning-of-a-new-diagnostic-era
#10
JOURNAL ARTICLE
Elisabeth V Goessinger, Philippe Gottfrois, Alina M Mueller, Sara E Cerminara, Alexander A Navarini
Psoriasis, a chronic inflammatory skin disease, affects millions of people worldwide. It imposes a significant burden on patients' quality of life and healthcare systems, creating an urgent need for optimized diagnosis, treatment, and management. In recent years, image-based artificial intelligence (AI) applications have emerged as promising tools to assist physicians by offering improved accuracy and efficiency. In this review, we provide an overview of the current landscape of image-based AI applications in psoriasis...
September 11, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/39225949/predictors-and-management-of-inadequate-response-to-jak-inhibitors-in-alopecia-areata
#11
JOURNAL ARTICLE
Xiaolin Zhang, Yiqun Jiang
Alopecia areata is a common autoimmune disorder characterized by non-scarring hair loss on the scalp or other hair-bearing surface. In recent years, Janus kinase (JAK) inhibitors have shown promise in the treatment of alopecia areata by disrupting the signaling pathways involved in immune-mediated hair follicle damage. However, some patients with alopecia areata exhibit insufficient responses to JAK inhibitors. This review aims to explore the predictive factors for poor responses to JAK inhibitors in patients with alopecia areata and to discuss alternative treatment strategies in such cases...
September 3, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/39098982/association-of-cardiovascular-disease-and-chronic-spontaneous-urticaria-a-case-control-study
#12
LETTER
Luis F Andrade, Zaim Haq, Parsa Abdi, Sarah G Brooks, Veronica Voronina, Michael J Diaz, Gil Yosipovitch
No abstract text is available yet for this article.
August 5, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/39078587/dapsone-use-in-dermatology
#13
REVIEW
Katie K Lovell, Rushan I Momin, Harneet Singh Sangha, Steven R Feldman, Rita O Pichardo
Dapsone, initially synthesized for textile dyeing, gained recognition in the 1930s for its antibacterial properties, leading to its utilization in dermatology for leprosy and dermatitis herpetiformis. Despite US Food and Drug Administration (FDA) approval for these conditions, dapsone's off-label uses have expanded, making it a valuable option in various dermatologic conditions. This review seeks to highlight the common uses of dapsone in its FDA indications and off-label indications. Diseases in which dapsone is considered first-line therapy or adjunctive therapy are reviewed, with highlights from the resources included...
July 30, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/39003351/sequencing-of-targeted-therapy-in-psoriasis-does-it-matter
#14
REVIEW
Nicole D Boswell, Shikha Singla, Kenneth B Gordon
With the continued development of biologics for the treatment of psoriasis, some patients have achieved optimal control, but a recommended biologic sequence if a biologic fails to initially improve the skin, termed primary nonresponse, or loses efficacy after initial improvement, termed secondary nonresponse, is still lacking. Primary and secondary nonresponse can occur with any class of biologics, and the type of nonresponse can drive the choice of whether to switch within a biologic class or to a different biologic class...
July 13, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/39134786/advances-in-the-application-of-noninvasive-skin-imaging-techniques-in-acne-scars
#15
REVIEW
Xiaoli Ning, Lingfan Jiang, Ruixing Yu, Yujun Sheng, Mengmeng Li, Hongfei Ouyang, Jingkai Xu, Yong Cui
Acne scarring is a common sequela of acne vulgaris, which seriously affects facial esthetics. The treatment options for acne scars vary depending on the development stage, color, type, and location of scarring. The objective and precise assessment of acne scars is a prerequisite for treatment, and it is also an important means of monitoring the treatment effect. The traditional methods to evaluate the types and severity grade of acne scars are primarily based on subjective assessment by physicians, which lacks objectivity and accuracy...
September 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/39060744/hidradenitis-suppurativa-new-targets-and-emerging-treatments
#16
REVIEW
Julia L Gao, Tracey S Otto, Martina L Porter, Alexa B Kimball
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that can be challenging to treat. Biologics and targeted small molecules have become an increasingly popular area of investigation for therapeutic development for moderate-to-severe HS, though only three biologics-adalimumab, secukinumab, and bimekizumab-have received US Food and Drug Administration (FDA) or European Medicines Evaluation Agency approval for treating HS. Promising agents under investigation are targeting interleukin 17A/F, JAK/STAT pathway, interleukin 36, interleukin 1, and more...
September 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38982032/lichen-planus-what-is-new-in-diagnosis-and-treatment
#17
REVIEW
Burak Tekin, Fangyi Xie, Julia S Lehman
Lichen planus (LP), an idiopathic, multifaceted chronic inflammatory disease with a heterogeneous clinical presentation, affects approximately 0.5-1% of the population. The various clinical manifestations of LP fall into three broad categories, namely cutaneous, appendageal, and mucosal, with further subclassification depending on the morphology and distribution patterns of individual lesions. There is mounting evidence that LP has systemic associations, including autoimmune conditions, glucose intolerance, dyslipidemia, and cardiovascular disorders...
September 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38967901/clinical-efficacy-and-safety-of-interleukin-17-inhibitors-in-treating-patients-with-erythrodermic-psoriasis-a-retrospective-cohort-three-center-study
#18
JOURNAL ARTICLE
Yu Lan, Xiaoyan Wu, Linya Ni, Yuhua Liu, Tianmeng Yan, Dejian Duan, Zhenying Zhang
No abstract text is available yet for this article.
July 5, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38954226/efficacy-and-safety-of-brodalumab-an-anti-interleukin-17-receptor-a-monoclonal-antibody-for-palmoplantar-pustulosis-16-week-results-of-a-randomized-clinical-trial
#19
JOURNAL ARTICLE
Yukari Okubo, Satomi Kobayashi, Masamoto Murakami, Shigetoshi Sano, Natsuko Kikuta, Yoshiumi Ouchi, Tadashi Terui
BACKGROUND: Palmoplantar pustulosis (PPP), a refractory skin disease characterized by repeated eruptions of sterile pustules and vesicles on palms and/or soles, involves interleukin-17 pathway activation. Brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, is being investigated for use in PPP treatment. OBJECTIVE: The aim was to assess the efficacy and safety of brodalumab in Japanese PPP patients with moderate or severe pustules/vesicles...
July 2, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38951460/human-inborn-errors-of-immunity-in-pyoderma-gangrenosum-a-systematic-review
#20
JOURNAL ARTICLE
Yasmine Oprea, Daniel R Antohi, Morgan Vague, Caroline Delbourgo Patton, Benedict Wu, Alex G Ortega-Loayza
BACKGROUND AND OBJECTIVE: Pyoderma gangrenosum (PG) is a rare ulcerative neutrophilic dermatosis that can be associated with primary immunodeficiency. The pathogenesis of PG has not yet been elucidated, although contributions from dysregulation of the immune system in patients with apparent genetic predispositions have been postulated. We conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-guided systematic review with the objective of identifying inborn errors of immunity in the presence of PG as well as their clinical characteristics of severity including number of PG lesions and anatomic areas affected, and treatment outcomes...
July 1, 2024: American Journal of Clinical Dermatology
journal
journal
34795
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.